Quince Therapeutics forms Scientific Advisory Board to advance LAM-001
Quince Therapeutics has formed a Scientific Advisory Board (SAB) comprising leading clinicians to support the development of LAM-001, an inhaled formulation of rapamycin. The SAB will guide the therapy across multiple pulmonary indications, including PH-ILD, BOS, and SAPH. The company plans to initiate Phase 2b trials for PH-ILD in mid-2026 and Phase 2 studies for SAPH in late 2026.
*this image is generated using AI for illustrative purposes only.
Quince Therapeutics, Inc. has established a Scientific Advisory Board (SAB) composed of internationally recognized experts in pulmonary medicine to support the advancement of LAM-001. LAM-001 is an inhaled formulation of rapamycin, an mTOR inhibitor designed to enhance pulmonary delivery and reduce systemic exposure. The formation of the SAB aims to accelerate the development of this disease-modifying therapy for serious underserved pulmonary conditions.
The SAB will be instrumental in progressing LAM-001 across multiple indications, including pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital, will serve as the Chairman of the SAB. He emphasized the potential of LAM-001 to provide a much-needed treatment option that may be used in conjunction with existing therapies.
Scientific Advisory Board Members
The SAB includes distinguished clinicians and researchers with extensive experience in pulmonary vascular disease and advanced lung conditions:
| Name | Role | Affiliation |
|---|---|---|
| Paul Yu, M.D., Ph.D. | Chairman of SAB | Massachusetts General Hospital, Harvard Medical School |
| Aaron Waxman, M.D., Ph.D. | Member | Brigham and Women's Hospital, Harvard Medical School |
| Steven Nathan, M.D., F.C.C.P. | Member | Inova Health System, University of Virginia |
| Steve Hays, M.D. | Member | UCSF Advanced Lung Disease and Lung Transplant Program, University of California, San Francisco |
| Robert Baughman, M.D. | Member | University of Cincinnati |
Clinical Development Pipeline
LAM-001 is currently being evaluated in several clinical programs. The company is advancing LAM-001 into a Phase 2b trial for PH-ILD, with initiation planned for mid-2026 and data anticipated in the first quarter of 2028. PH-ILD affects an estimated 86,000 patients in the U.S. and 120,000 in Europe.
A Phase 2 study in BOS is fully enrolled, with data expected in the first quarter of 2027. BOS is a serious complication following lung transplantation affecting an estimated 17,000 patients in the U.S. and 11,000 in Europe. Additionally, Quince Therapeutics plans to initiate a Phase 2 study for SAPH in late 2026. SAPH is a severe complication of sarcoidosis with no approved therapy, affecting an estimated 60,000 patients in the U.S. and Europe.
About LAM-001
LAM-001 is a proprietary, investigational, once-daily inhaled formulation of sirolimus. Its mechanism involves inhibiting mTOR-mediated pulmonary arterial smooth muscle cell proliferation and exerting direct anti-fibrotic activity. These effects are particularly relevant in conditions like PH-ILD, where vascular remodeling and progressive fibrosis occur simultaneously. The therapy is designed to offer a potential disease-modifying option by enhancing pulmonary delivery while minimizing systemic exposure.
What are the potential regulatory pathways and accelerated approval opportunities for LAM-001 given the lack of approved therapies for SAPH?
How will Quince Therapeutics address manufacturing and scalability challenges for the inhaled formulation of rapamycin as it moves into Phase 2b trials?
What strategic partnerships or collaborations might Quince pursue to support the commercialization of LAM-001 across multiple indications?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
